Haleon stock dips as Deutsche Bank cuts target for consumer-health group
Published on 09/09/2026 at 17:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Haleon stock (ISIN GB00BMX86B70) closed at GBP 337.30 on the London Stock Exchange on September 8, 2026, marking a 1.75% decline from the prior trading session and setting the tone for a cautious start to September 9, 2026 for investors in the consumer-health company.
Deutsche Bank trims Haleon price target
According to MarketBeat on September 9, 2026, Deutsche Bank Aktiengesellschaft lowered its price target for Haleon from 335 pence to 320 pence and reiterated a sell rating on the stock.
A summary of London broker moves published by Morningstar Alliance News also highlights that Deutsche Bank Research reduced its Haleon price target to 320 pence from 335 pence and kept the recommendation at sell on September 9, 2026, underlining concerns about valuation relative to the bank’s earnings expectations.
As reported by Investing.com on September 9, 2026, Deutsche Bank’s adjustment for Haleon came alongside rating and target changes for several European consumer names, with the new 320 pence target sitting below the current market level, sharpening the downside implied by the sell call.
Recent earnings and profitability metrics
Haleon’s most recent quarterly results provide context for the cautious stance. According to MarketBeat, the company last reported its quarterly earnings on July 30, 2026, posting earnings per share of GBX 8.60 for the period.
In the same report, MarketBeat notes that Haleon generated a return on equity of 9.89 percent and achieved a net margin of 14.55 percent in that latest quarter, underscoring that the consumer-health group is profitable but still being critiqued by some analysts for the balance between growth and valuation.
Based on data compiled by MarketBeat, research analysts on average expect Haleon to deliver 19.5033282 pence in earnings per share for the current fiscal year 2026, implying that the July 30, 2026 quarter’s GBX 8.60 EPS is a little under half of the full-year forecast and framing the trajectory the company needs to maintain over the remaining reporting periods.
Valuation, consensus and investor takeaways
The Deutsche Bank target cut to 320 pence from 335 pence comes against a broader backdrop of more neutral views on Haleon. According to the same MarketBeat overview on September 9, 2026, Haleon currently carries an average rating of Hold from covering analysts and a consensus target price of 396.50 pence, which stands notably above Deutsche Bank’s reduced 320 pence level.
That quantified gap between the 320 pence target from Deutsche Bank and the 396.50 pence consensus cited by MarketBeat highlights a roughly 76.50 pence difference in expectations, illustrating how Deutsche Bank’s more cautious stance undercuts the broader analyst community’s view on Haleon’s potential upside.
The price action around September 8, 2026 reflects how these mixed views are feeding into trading. Haleon stock closed at GBP 337.30 on the London Stock Exchange on September 8, 2026, down 1.75 percent from the previous session, as reported in a trading wrap on Ad-hoc corporate news, leaving the shares trading above Deutsche Bank’s new 320 pence target but below the consensus 396.50 pence figure.
Haleon stock price level and trading context
For investors focusing on the latest close as a reference, Haleon stock’s GBP 337.30 closing level on the London Stock Exchange on September 8, 2026, as highlighted in the Ad-hoc corporate news piece, represents a 1.75 percent decline from the prior session and serves as the most recent completed trading reference for the stock.
Key data on Haleon stock
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Ticker: HLN
- Trading venue: London Stock Exchange
- Price (as of September 8, 2026): 337.30 GBP
- Sector / Industry: Consumer Health Products
- Index membership: FTSE 100
